---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-091494"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:48:50.032732+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# NRX Pharmaceuticals enters $2M at-the-market equity offering with H.C. Wainwright

## Summary
- At-the-market offering of up to $2,000,000 of common stock; sales at market prices via Nasdaq.
- H.C. Wainwright will receive 3.0% commission on gross proceeds plus expense reimbursement.
- Sales are made under an effective shelf registration statement (S-3) filed June 2022.
- Company is not obligated to sell any shares; agreement terminates upon full sale or earlier termination.
- Customary reps, warranties, indemnification, and conditions apply to the agreement.

## SEC filing metadata
- accession: 0001104659-23-091494
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/0001104659-23-091494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/tm2323641d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-091494
- JSON: https://secwatch.observer/filing/0001104659-23-091494.json
- Plain text: https://secwatch.observer/filing/0001104659-23-091494.txt

## Key facts
- Material Agreements
  NRX Pharmaceuticals, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at up to $2,000,000 (effective 2023-08-14).
  - Action: entry
  - Agreement: atm program
  - Counterparty: H.C. Wainwright & Co., LLC
  - Value: up to $2,000,000
  - Effective: 2023-08-14
  source text: On August 14, 2023, NRX Pharmaceuticals, Inc. (the “Company”), entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $2,000,000 (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923091494/0001104659-23-091494-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.